Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3968 A systematic review of hepatic transplantation for neuroendocrine liver metastases – Focus on long-term outcomes

Introduction: Neuroendocrine neoplasms frequently metastasise to the liver. Neuroendocrine liver metastases (NELM) may be treated with a broad range of therapeutic options - liver transplantation (LT) being an uncommon, potentially promising, but controversially debated approach.

Conference:

Presenting Author: Clift A

Authors: Palaniappan V, Lei C, Frilling A, Clift A,

Keywords: liver metastases, transplantation, systematic review,

#3850 [177Lu]-oxodotreotide in the treatment of gastroenteropancreatic neuroendocrine tumors – Patient profile in the REAL LU study (pRospective obsErvationAL study to assess the effectiveness and outcomes associated with LUtathera)

Introduction: Somatostatin (SST) receptor (SSTR) radioligand therapy is an option for highly SSTR-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The REAL LU study [NCT04727723] is evaluating the effectiveness of [177Lu]-oxodotreotide (LuO) in unresectable/metastatic, progressive, SSTR-expressing, Grade (G)1 or G2 GEP-NETs in clinical practice.

Conference:

Presenting Author:

Authors: Lastoria S, Tafuto S, Rodari M, Lania A, Sansovini M,

Keywords: REAL LU, GEP-NET, RLT, neuroendocrine tumor, radioligand therapy, [177Lu]-oxodotreotide,

#3635 Non-responders to Peptide Receptor Radionuclide Therapy (PRRT) – A single center retrospective analysis

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has become the standard of care for patients (pts) with positive somatostatin receptor image, grade (G)1/2 gastrointestinal (GI) neuroendocrine tumors (NETs) after Somatostatin Analogues (SSAs) failure.

Conference:

Presenting Author: Laffi A

Authors: Laffi A, Rodari M, Lania A, Zerbi A, Elisabetta L,

Keywords: PRRT, neuroendocrine tumor, NET, Nuclear Medicine,

#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience

Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Smiroldo V

Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, Zerbi A,

Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan,

#2247 Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience

Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Smiroldo V, Carnaghi C, Lania A, Bonifacio C, Pepe G,

Keywords: CapTem, metastatic neuroendocrine tumors,